PHILADELPHIA -- Researchers may have found another autoantigen involved in idiopathic membranous nephropathy, they reported here. In a study of 154 patients who did not have antibodies to PLA2R1 -- ...
Antibodies to neutral endopeptidase, the first podocyte antigen described in human membranous nephropathy, are responsible for alloimmune neonatal membranous nephropathy, which develops in children of ...
Membranous location of EGFR immunostaining is associated with good prognosis in renal cell carcinoma
Our study population consisted of 134 consecutive patients who underwent radical nephrectomy for RCC between 1995 and 1999 at Tampere University Hospital. The median age of the patients (83 men and 51 ...
Please provide your email address to receive an email when new articles are posted on . Proteinuria levels don’t predict lupus nephritis type, suggesting separate study approaches are needed. Distinct ...
Rituximab (Rituxan, Genentech) should replace cyclosporine for the treatment of primary membranous nephropathy, say editorialists commenting on the results of the Membranous Nephropathy Trial of ...
Membranous nephropathy, also called membranous glomerulopathy, is a kidney disease that affects the filters, or glomeruli, of your kidneys. These filters usually help remove waste and fluids. But when ...
Research conducted by a pair of physicians has led to the development of a test that can help diagnose membranous nephropathy in its early stages. The test, which is currently only offered in the ...
B-cell anomalies play a role in the pathogenesis of membranous nephropathy. B-cell depletion with rituximab may therefore be noninferior to treatment with cyclosporine for inducing and maintaining a ...
Everest Medicines, a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, announced positive results in the ongoing ...
Dublin, July 24, 2023 (GLOBE NEWSWIRE) -- The "Idiopathic Membranous Nephropathy (IMN) Market Insights, Epidemiology and Forecast to 2032" report has been added to ResearchAndMarkets.com's offering.
This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Beck: Sure. MN was ...
Daniel C. Cattran, MD The MENTOR study is poised to change first-line-treatment recommendations for idiopathic membranous nephropathy. The Membranous Nephropathy Trial of Rituximab (MENTOR) study is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback